(PharmaNewsWire.Com, April 22, 2024 ) The report "Cystatin C Assay Market by Product (Analyzers, Kits, Reagents), Method (ELISA, PETIA, IFA, CLIA, PENIA), Application (Diagnostics, Research), Sample Type (Blood, Urine), End User (Hospitals, Clinical Laboratories), Region- Global Forecast to 2028", is projected to reach USD 540 million by 2028 from USD 377 million in 2023, at a CAGR of 7.5% during the forecast period
The growth of this market is majorly driven by growing number of old age population and rising number of kidney diseases. However, high development costs of cystatin C assay may challenge the growth of this market.
UK in European cystatin C assay market to witness the highest shares during the forecast period.
The European cystatin C assay market is segmented into Germany, France, the UK, Italy, Spain, and the Rest of Europe. UK is projected to occupy the highest share during the forecast period. Market growth is attributed to the rising geriatric population & chronic diseases, increasing number of accredited clinical & hospital laboratories, growing government healthcare expenditure.
Clinical laboratories in End user’ cystatin C assay market to witness the second highest growth rate during the forecast period.
Based on the end user, cystatin C assay market is segmented into hospitals, clinical laboratories, and pharmaceutical & biotechnology companies & CROs & academic research institutes The clinical laboratories registered the second highest CAGR, due to the growing number of clinical tests performed in laboratories and the increasing number of accredited laboratories, and serving as centralized hubs for diagnostic testing, where a wide array of tests, including cystatin C assays which support market growth.
China dominates the Asia Pacific cystatin C assay market.
The APAC cystatin C assay market is segmented into Japan, China, India, and Rest of Apac. In 2022, China accounted for the largest share of the Asian cystatin C assay market. The large share of China can be attributed to the government efforts to increase awareness about the early detection of diseases and regular health check-ups; rising healthcare expenditure; the increasing number of hospitals and clinical diagnostic laboratories in India and China; and strengthening research base for diagnostic procedures across India, China, and Japan, rising cases of CKD.
The significant players in the cystatin C assay are Siemens Healthcare GmbH (Germany), Thermo Fisher Scientific Inc. (US), Abbott (US), Roche Diagnostics Limited.(Switzerland), and Bio-Techne (US), Randox Laboratories Ltd. (UK), DiaSys Diagnostic Systems GmbH (Germany), and Eurolyser Diagnostica GmbH (Austria)
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
